Clinical significance of cytogenetic changes in childhood T-cell acute lymphoblastic leukemia: results of the multicenter group Moscow-Berlin (MB)

• Published in: Leukemia & lymphoma Vol. 60; no. 2; pp. 426 - 432
• Main Authors: Olshanskaya, Yulia, Kazakova, Anna, Tsaur, Grigory, Zerkalenkova, Elena, Soldatkina, Olga, Aprelova, Eugenia, Plekhanova, Olga, Gindina, Tatiana, Mercur'ev, Dmitry, Barhkatov, Ildar, Baidun, Ludmila, Bydanov, Oleg, Lagoiko, Svetlana, Tallen, Gesche, Rumiantseva, Julia, Rumiantsev, Alexander, Karachunskii, Alexander, Henze, Guenter
• Format: Journal Article
• Language: English
• Published: United States Taylor & Francis 28.01.2019
• Subjects: Adolescent; Biomarkers; Biomarkers, Tumor; Child; Child, Preschool; Chromosome Aberrations; Female; FISH; Gene Rearrangement; Humans; In Situ Hybridization, Fluorescence; Incidence; Infant; Karyotyping; Male; pediatric; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma - diagnosis; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma - genetics; Prognosis; T-cell acute lymphoblastic leukemia; FISH; prognosis; T-cell acute lymphoblastic leukemia; pediatric
• ISSN: 1042-8194; 1029-2403
• DOI: 10.1080/10428194.2018.1485904

The prognostic significance of genetic lesions in T-cell ALL still needs to be elucidated. Karyotyping and FISH were performed in samples from 120 patients with T-cell ALL registered in the trial Moscow-Berlin 2008. Most frequent rearrangements were TLX3 (N = 29; 24%) and TAL1 (N = 18; 15%), followed by KMT2A (N = 6; 5%), TLX1 (N = 5; 4.2%), and 11p13-15 (N = 5; 4.2%). In 16.7% of patients, the karyotype was normal, and in 30.8% 'other' aberrations were seen. Patients with a normal karyotype, TAL1, or KMT2A rearrangements had the most favorable outcome (probability of event free survival (pEFS): 82% ± 6%), while prognosis for patients with TLX3 and TLX1 rearrangements and 'other' aberrations was less favorable (pEFS: 62% ± 6%). Worst outcome was observed for five patients with 11p rearrangements (pEFS: 20% ± 18%). In summary, three subgroups of patients with T-cell ALL with significantly different outcomes could be defined by cytogenetic profiling.